PDS Biotechnology adds three directors after four board resignations
PDS Biotechnology reported that four directors resigned from its Board effective October 18, 2026, and the Board appointed three new directors that day to fill three of the four vacancies. The Board fixed its size at seven directors and reconstituted its committees, which matters to shareholders because it changes who oversees audit, compensation and governance.
Key points
- Kamil Ali-Jackson, Stephen Glover, Gregory Freitag and Otis Brawley resigned effective October 18, 2026; the filing says none resulted from a disagreement with the Company.
- Deborah A. Ramsdell, John A. Dawson CBE and Bruce Wendel were appointed directors on October 18, 2026, and the Board set its size at seven.
- Each new director received a nonqualified stock option to purchase 22,700 shares, vesting in three annual installments.
- James Banaag chairs the Audit Committee and is designated an audit committee financial expert; Bruce Wendel chairs the Nominating and Corporate Governance Committee.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 20, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.